Kbc Group Nv Bei Gene, Ltd. Transaction History

Kbc Group Nv

$33.1 Billion
Q3 2024

A detailed history of Kbc Group Nv transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Kbc Group Nv holds 8,937 shares of BGNE stock, worth $1.62 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

8,937

Previous 8,937 -0.0%

Holding current value

$1.62 Million

Previous $1.28 Million 57.33%

% of portfolio

0.01%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$158.67 - $201.58 $382,712 - $486,210	-2,412 Reduced 21.25%	8,937 $1.61 Million
Q3 2023 Feb 15, 2024	SELL	$179.87 - $225.13 $433,846 - $543,013	-2,412 Reduced 21.25%	8,937 $1.61 Million
Q2 2023 Feb 15, 2024	SELL	$178.3 - $266.78 $369,615 - $553,034	-2,073 Reduced 15.44%	11,349 $2.02 Million
Q1 2023 May 04, 2023	SELL	$215.53 - $274.5 $446,793 - $569,038	-2,073 Reduced 15.44%	11,349 $0
Q4 2022 Feb 14, 2024	SELL	$125.51 - $229.3 $398,368 - $727,798	-3,174 Reduced 21.85%	11,349 $2.5 Million
Q3 2022 Feb 15, 2024	BUY	$131.8 - $202.24 $591,123 - $907,046	4,485 Added 50.18%	13,422 $1.81 Million
Q3 2022 Nov 08, 2022	SELL	$131.8 - $202.24 $145,111 - $222,666	-1,101 Reduced 7.58%	13,422 $1.81 Million
Q2 2022 Feb 14, 2024	BUY	$121.11 - $216.05 $40,087 - $71,512	331 Added 2.33%	14,523 $2.35 Million
Q2 2022 Jul 26, 2022	BUY	$121.11 - $216.05 $40,087 - $71,512	331 Added 2.33%	14,523 $2.35 Million
Q1 2022 Feb 14, 2024	BUY	$146.52 - $269.56 $18,315 - $33,695	125 Added 0.89%	14,192 $2.68 Million
Q1 2022 May 06, 2022	BUY	$146.52 - $269.56 $18,315 - $33,695	125 Added 0.89%	14,192 $2.68 Million
Q4 2021 Feb 14, 2024	BUY	$248.56 - $389.34 $1.28 Million - $2 Million	5,130 Added 57.4%	14,067 $3.81 Million
Q4 2021 Feb 03, 2022	BUY	$248.56 - $389.34 $2.17 Million - $3.4 Million	8,720 Added 163.08%	14,067 $3.81 Million
Q3 2021 Nov 10, 2021	SELL	$249.6 - $403.14 $3,244 - $5,240	-13 Reduced 0.24%	5,347 $1.94 Million
Q2 2021 Aug 11, 2021	SELL	$292.75 - $367.01 $72,016 - $90,284	-246 Reduced 4.39%	5,360 $1.84 Million
Q1 2021 Apr 26, 2021	SELL	$260.64 - $382.12 $299,214 - $438,673	-1,148 Reduced 17.0%	5,606 $1.95 Million
Q4 2020 Feb 10, 2021	BUY	$221.31 - $316.61 $513,660 - $734,851	2,321 Added 52.36%	6,754 $1.75 Million
Q3 2020 Oct 28, 2020	BUY	$189.18 - $286.44 $53,348 - $80,776	282 Added 6.79%	4,433 $1.27 Million
Q2 2020 Aug 10, 2020	SELL	$123.9 - $195.41 $240,737 - $379,681	-1,943 Reduced 31.88%	4,151 $782,000
Q1 2020 May 04, 2020	BUY	$121.84 - $173.19 $15,839 - $22,514	130 Added 2.18%	6,094 $750,000
Q4 2019 Feb 11, 2020	BUY	$115.78 - $208.34 $297,091 - $534,600	2,566 Added 75.52%	5,964 $989,000
Q1 2019 May 10, 2019	BUY	$122.82 - $151.83 $95,308 - $117,820	776 Added 29.6%	3,398 $0
Q4 2018 Jan 31, 2019	BUY	$107.01 - $175.15 $280,580 - $459,243	2,622 New	2,622 $367,000

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.8B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.

Account